Q3 2024 Earnings Call Transcript October 31, 2024 Madrigal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Novo's Rival Drug Shows Promise, But Madrigal's First-Mover Advantage Keeps Investors Hooked--What's Next for This Rising ...

Madrigal Pharmaceuticals' Rezdiffra for NASH shows strong early demand, positioning the company as a market leader. Read why ...

CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor ...

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

Madrigal Pharmaceuticals Inc (MDGL) reports robust Q3 sales driven by Rezdiffra demand, while navigating increased SG&A ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has been given a consensus rating of “Moderate Buy” by the thirteen ratings firms that are presently covering the stock, Marketbeat ...

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with ...

Celebrations may be in order for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The ...

Bill Sibold, Chief Executive Officer of Madrigal, stated, “This will be the first AASLD Liver Meeting following the approval of Rezdiffra earlier this year, and the entire NASH community feels ...

Stacey Sears, portfolio manager at Emerald Advisers, sits down with InvestmentNews anchor Gregg Greenberg to offer her outlook for small-cap stocks in the face of such a magnificent run for large ...

2-Year U.S. Treasury Note Continuous Contract $102.738-0.008-0.01% 5-Year U.S. Treasury Note Continuous Contract $106.719-0.008-0.01% 10-Year U.S. Treasury Note Continuous Contract $109.531-0.016 ...